Clinical Infectious Diseases (CID)
Volume 61 Issue 3 August 1, 2015
http://cid.oxfordjournals.org/content/current

,
Immunogenicity, Safety, and Tolerability of 13-Valent Pneumococcal Conjugate Vaccine Followed by 23-Valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged ≥2 Years: An Open-Label Study
Catherine Cordonnier, Per Ljungman, Christine Juergens, Johan Maertens, Dominik Selleslag, Vani Sundaraiyer, Peter C. Giardina, Keri Clarke, William C. Gruber, Daniel A. Scott, and Beate Schmoele-Thoma for the 3003 Study Group
Clin Infect Dis. (2015) 61 (3): 313-323 doi:10.1093/cid/civ287
Abstract
OPEN ACCESS
Severe Streptococcus pneumoniae infections are frequent complications after hematopoietic stem cell transplant (HSCT). A 3-dose regimen of 13-valent pneumococcal conjugate vaccine, starting 3–6 months after HSCT and followed by a booster dose, may be required for adequate protection.